Cardiovascular

Latest News

AJMC
Impact of Functional Recovery on Patients Having Heart Surgery

October 10th 2024

This article describes the positive impact that actively managing functional recovery has on postacute placement for patients undergoing coronary artery bypass surgery.

doc measuring BP in pregnant woman-Andrey Popov-stock.adobe.com.jpeg
Association Between Hypertensive Disorders of Pregnancy, Cardiovascular Severe Maternal Morbidity During Delivery Hospitalization

October 3rd 2024

Measuring blood pressure | Image credit: Andrey Popov - stock.adobe.com
Stalled Progress in Reducing Black Mortality Rates: The Role of External Causes and COVID-19

September 30th 2024

Woman holding hand to heart in pain | Image credit: eddows – stock.adobe.com
Largest Study of Lp(a), Recurrent ASCVD Highlights Critical Risks and Need for Screening

September 24th 2024

DNA double helix | Image credit: Dr_Microbe – stock.adobe.com
The Role of Genetics in Cholesterol, Heart Disease Risk

September 24th 2024

Advancements in Population Health Strategies for Cardiovascular Risk Management

Experts discuss how lipoproteins drive atherosclerotic heart disease, review the different guidelines and recommendations on Lp(a) testing, and insights from clinical trials.

Hands holding a heart with a heartbeat on it and the words AJMC Insights
Continuing Medical Education
View All
October 13th 2024

Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction

1.0 Credits / Cardiology
October 13th 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
October 13th 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Dapagliflozin Cuts Risk of CV Death, Worsening of Heart Failure 26%, Whether Diabetes Present or Not
September 1st 2019

Dapagliflozin Cuts Risk of CV Death, Worsening of Heart Failure 26%, Whether Diabetes Present or Not

Mary Caffrey
Dapagliflozin, sold by AstraZeneca as Farxiga, cut the risk of cardiovascular (CV) death and worsening of heart failure (HF) by 26% among patients with reduced ejection fraction alongside standard of care, according to results of a landmark phase 3 study presented Sunday at the European Society of Cardiology 2019 Congress. Results confirmed that the sodium glucose co-transporter 2 (SGLT2) inhibitor, already approved to treat type 2 diabetes (T2D), is just as effective in preventing CV death and HF events in patients who do not have T2D.
Apixaban Shows Lower Rate of Bleeding in Large French Real-World Data Study
September 1st 2019

Apixaban Shows Lower Rate of Bleeding in Large French Real-World Data Study

Mary Caffrey
Data in the real-world study included a large share of patients over the age of 80, who are representative of those doctors see in clinical practice.
FDA Grants Fast Track Designation for Dapagliflozin to Prevent Kidney Failure
August 27th 2019

FDA Grants Fast Track Designation for Dapagliflozin to Prevent Kidney Failure

Matthew Gavidia
Dapagliflozin’s fast track designation follows findings from last year’s DECLARE-TIMI trial, a cardiovascular outcomes trial that showed the drug’s significant impact on delaying the loss of kidney function and reducing hospitalization risk for heart failure.
5 Things to Look for at the European Society of Cardiology 2019 Congress
August 23rd 2019

5 Things to Look for at the European Society of Cardiology 2019 Congress

Mary Caffrey
Studies on anticoagulants and SGLT2 inhibitors, and guidelines for dyslipidemia and more are anticipated at the meeting.
Air Pollution Found to Be Possible Cause of Premature Death Rates
August 22nd 2019

Air Pollution Found to Be Possible Cause of Premature Death Rates

Matthew Gavidia
Researchers found evidence correlating toxic air pollutants to increased respiratory and cardiovascular death rates.
Site Logo
August 19th 2019

Prescription Omega-3 Fatty Acids Effectively Reduce Triglycerides, AHA Says in Advisory

Mary Caffrey
Interest in omega-3 fatty acids have increased since publication of the results of REDUCE-IT.
Improving Heart Health at Age 50 Can Reduce Dementia Risk Later in Life
August 9th 2019

Improving Heart Health at Age 50 Can Reduce Dementia Risk Later in Life

Laura Joszt, MA
People who have better cardiovascular health, as scored by the American Heart Association's Life's Simple 7, at age 50 have a lower risk of developing dementia over the next 25 years, according to a new study.
Rejected, Unfilled PCSK9 Inhibitor Prescriptions Linked to Higher Risk of Cardiovascular Events
July 23rd 2019

Rejected, Unfilled PCSK9 Inhibitor Prescriptions Linked to Higher Risk of Cardiovascular Events

Jaime Rosenberg
Patients were 16% more likely to have a cardiovascular event if their prescription was rejected and 21% more likely to have a cardiovascular event if they did not fill their prescription.
HHS Unveils 5 New Payment Models to Transform Kidney Disease Care
July 10th 2019

HHS Unveils 5 New Payment Models to Transform Kidney Disease Care

Jaime Rosenberg
Following an executive order from President Donald Trump, HHS announced the launch of Advancing American Kidney Health, an initiative to improve the health of the 37 million Americans living with kidney disease, by releasing 5 new payment models.
Site Logo
June 30th 2019

2019 ADA Coverage: Renal Outcomes

Mary Caffrey
Coverage of DECLARE, CARMELINA, and other studies that highlight the connection between diabetes and renal outcomes
Top 5 AJMC® Articles of June 2019
June 30th 2019

Top 5 AJMC® Articles of June 2019

Here are the top 5 articles for the month of June.
Site Logo
June 29th 2019

CREDENCE: First Renal Outcomes Trial Finds Canagliflozin Cuts Risk of Renal Failure, Death; Prompts ADA Updates

Mary Caffrey
Presentations at 2 major scientific conferences showed that the SGLT2 inhibitor cut the risk of renal failure or death by 30% and had renal benefits for patients with and without previous cardiovascular disease.
Site Logo
June 29th 2019

Outcomes Trials Set Stage for Future of Diabetes Management in Patients With Renal Disease

Joseph E. Cruz, PharmD, BCPS Mary Bridgeman, PharmD, BCPS, BCGP
Two doctors of pharmacy review the impact of recent outcomes trials for newer classes of type 2 diabetes therapy.
FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm
June 28th 2019

FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm

Mary Caffrey
The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.
Site Logo
June 28th 2019

From the Editor-in-Chief: Evolving Role of T2D Therapy, From Secondary to Primary Prevention

Robert A. Gabbay, MD, PhD, FACP
Evidence that newer type 2 diabetes therapies offer cardiovasular and renal benefits offer opportunities for greater collaboration among specialists and more value for patients. Payers must take notice.
Using Real-World Evidence to Understand Disparities, Clinical Inertia
June 18th 2019

Using Real-World Evidence to Understand Disparities, Clinical Inertia

Mary Caffrey
Merck's Center for Observational and Real-World Evidence has spent several years gathering evidence on clinical inertia and is now working on solutions to overcome it at the point of care.
5 Takeaways From the ADA Scientific Sessions
June 14th 2019

5 Takeaways From the ADA Scientific Sessions

Mary Caffrey
There was something for everyone at the American Diabetes Association (ADA) Scientific Sessions, held June 7-11, 2019, in San Francisco, California.
Site Logo
June 12th 2019

More CV, Renal Outcomes at ADA: CREDENCE, CARMELINA, CAROLINA

Mary Caffrey
The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.
Site Logo
June 11th 2019

Highlighting Links Between Kidney, CV Disease in Diabetes

Mary Caffrey
The connections among diabetes, cardiovascular (CV) disease, and kidney failure have been a theme of the 79th Scientific Sessions of the American Diabetes Association, which featured a joint session with the American Society of Nephrology.
This Week in Managed Care: May 31, 2019
May 31st 2019

This Week in Managed Care: May 31, 2019

This week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to Amarin’s Vascepa for a cardiovascular indication.
Site Logo
May 29th 2019

Combining DPP-4 Inhibitor, SGLT2 Inhibitor for Type 2 Diabetes Cost-Effective Over Time, AJMC® Study Says

A Policy article in the May issue of The American Journal of Managed Care® suggests that sequential addition of SGLT2 inhibitors to DPP-4 inhibitors may be considered cost-effective compared with standard treatment using sulfonylurea and insulin for patients with type 2 diabetes who have difficulty maintaining glycated hemoglobin of seven percent or less on metformin alone.
Heart Disease Topped Reasons for Excess Deaths in Puerto Rico After Hurricane Maria
April 19th 2019

Heart Disease Topped Reasons for Excess Deaths in Puerto Rico After Hurricane Maria

Allison Inserro
Heart disease was the number one reason for “excess deaths” after Hurricane Maria struck Puerto Rico in September 2017.
As Comorbidities Pile Up, True Diabetes Cost Measured by More Than Insulin, Panel Says
April 14th 2019

As Comorbidities Pile Up, True Diabetes Cost Measured by More Than Insulin, Panel Says

Allison Inserro
For endocrinologists, a cardiologist, a diabetes educator, and a room full of fellow health workers, the cost of doing nothing—not just to treat diabetes, but also to prevent it— is what feeds into the exorbitant cost of the disease, according to presentations and a panel at the inaugural meeting of the Institute for Value Based Medicine (IVBM) in Diabetes, an initiative of The American Journal of Managed Care®.
Lost Productivity From Heart Attack, Stroke Are Twice Direct Medical Costs, Study Finds
April 9th 2019

Lost Productivity From Heart Attack, Stroke Are Twice Direct Medical Costs, Study Finds

Mary Caffrey
The results come as US professional societies are updating primary prevention guidelines in cardiology.
Site Logo
April 8th 2019

Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population

Maureen J. Lage, PhD
Previous research overstated the generalizability of the Exenatide Study of Cardiovascular Event Lowering trial results by omitting the restriction on the percentage of patients without a prior cardiovascular event.
Site Logo
April 8th 2019

Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”

Eric T. Wittbrodt, PharmD, MPH James M. Eudicone, MS, MBA Kelly F. Bell, PharmD, MSPhr Devin M. Enhoffer, PharmD Keith Latham, PharmD Jennifer B. Green, MD
The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.
Amarin Files Supplemental NDA With FDA for Vascepa Based on REDUCE-IT Results
April 4th 2019

Amarin Files Supplemental NDA With FDA for Vascepa Based on REDUCE-IT Results

Wallace Stephens
Based on recently published results of the REDUCE-IT study, pharmacuetical company Amarin has submitted a supplemental new drug application (sNDA) to the FDA for an expanded label for its leading drug Vascepa. Also, the American Diabetes Association has included the drug in a mid-year update to its 2019 Standards of Medical Care in Diabetes.
Site Logo
March 31st 2019

EBDM March 2019: Clinical Updates

Mary Caffrey Laura Joszt, MA Kelly Davio
Site Logo
March 28th 2019

Managing Cholesterol With PCSK9 Inhibitors and Overcoming Operational Challenges in Practice

Laura Joszt, MA
Panelists discuss what PCSK9 inhibitors are, the evidence to support them, and challenges with operationalizing them in practice.
Incentivizing Healthy Eating in Medicare, Medicaid Is Cost Effective, Study Finds
March 22nd 2019

Incentivizing Healthy Eating in Medicare, Medicaid Is Cost Effective, Study Finds

Laura Joszt, MA
Researchers found that a prescription for healthy food can improve health outcomes for beneficiaries in Medicare and Medicaid.
<1
...
34567891011
...
22>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo